The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Open accessAbstract
Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy, followed by radiation plus concomitant and adjuvant temozolomide. The treatment of recurrent glioblastoma continues to be a moving target as new therapeutic principles enrich the standards of care for newly diagnosed disease. We reviewed PubMed and American Society of Clinical Oncology abstracts from January 2006 to January 2012 to identify clinical trials investigating the treatment of recurrent or progressive glioblastoma with nitrosoureas, temozolomide, bevacizumab, and/or combinations of these agents. At recurrence, a minority of patients are eligible for second surgery or reirradiation, based on appropriate patient selection. In temozolomide-pretreated patients, progression-free survival rates at 6 months of 20%-30% may be achieved either with nitrosoureas, temozolomide in various dosing regimens, or bevacizumab. Combination regimens among these agents or with other drugs have not produced evidence for superior activity but commonly produce more toxicity. More research is needed to better define patient profiles that predict benefit from the limited therapeutic options available after the current standard of care has failed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationOstrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationWen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou223 · Cited by 1,718
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Self-citationBevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationGlioblastoma survival in the United States before and during the temozolomide era
Johnson, D. R., & O’Neill, B. P. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0749-4 · Cited by 720
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Self-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Self-citationTaal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465
Current concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Self-citationLamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K. L., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 421
Self-citationPhase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Self-citationMulticenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Gutin, P. H., Iwamoto, F. M., Beal, K., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S., Yamada, Y., Chang, J., & Abrey, L. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.043 · Cited by 370
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
Park, J. K., Hodges, T., Arko, L., Shen, M., Dello Iacono, D., McNabb, A., Olsen Bailey, N., Kreisl, T. N., Iwamoto, F. M., Sul, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0582 · Cited by 359
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M. C., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 297
Self-citationMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
Self-citationMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Self-citationTemozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Brada, M., Stenning, S., Gabe, R., Thompson, L. C., Levy, D., Rampling, R., Erridge, S., Saran, F., Gattamaneni, R., Hopkins, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1932 · Cited by 249
Narayana, A., Kelly, P., Golfinos, J., Parker, E., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Raza, S., Medabalmi, P., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17492 · Cited by 243
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
Nghiemphu, P. L., Liu, W., Lee, Y., Than, T., Graham, C., Lai, A., Green, R. M., Pope, W. B., Liau, L. M., Mischel, P. S., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000345668.03039.90 · Cited by 234
Self-citationPhase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 231
Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V, Franceschi, E., Biscuola, M., Blatt, V, Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 228
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Self-citationReardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Sampson, J. H., Sathornsumetee, S., McLendon, R. E., Herndon, J. E., Marcello, J. E., Norfleet, J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605412 · Cited by 206
Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., et al. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070169 · Cited by 197
Understanding Glioblastoma Tumor Biology: The Potential to Improve Current Diagnosis and Treatments
Kesari, S. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.005 · Cited by 155
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma
Wick, W., Steinbach, J. P., Küker, W., DICHGANS, J., BAMBERG, M., & Weller, M. (2004) · Neurology · doi:10.1212/01.wnl.0000127617.89363.84 · Cited by 155
Self-citationRaizer, J. J., Grimm, S. A., Chamberlain, M. C., Nicholas, M. K., Chandler, J. P., Muro, K., Dubner, S., RADEMAKER, A. W., Renfrow, J. J., & Bredel, M. (2010) · Cancer · doi:10.1002/cncr.25462 · Cited by 153
Bevacizumab and daily temozolomide for recurrent glioblastoma
Desjardins, A., Reardon, D. A., Sykes, A. D., Marcello, J. E., Herndon, J. E., Bailey, L., Peters, K. B., Friedman, H. S., & Vredenburgh, J. J. (2011) · Cancer · doi:10.1002/cncr.26381 · Cited by 149
‘Recurrent’ glioblastoma multiforme, when should we reoperate?
Barbagallo, G. M. V., Jenkinson, M. D., & Brodbelt, A. R. (2008) · British Journal of Neurosurgery · doi:10.1080/02688690802182256 · Cited by 146
Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis.
Sharma, S., Salehi, F., Scheithauer, B. W., Rotondo, F., Syro, L. V., & Kovács, K. (2009) · PubMed · Cited by 146
Gilbert, M. R., Kuhn, J., Lamborn, K. R., Lieberman, F. S., Wen, P. Y., Mehta, M. P., Cloughesy, T. F., Lassman, A. B., DeAngelis, L. M., Chang, S. M., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0650-1 · Cited by 140
Self-citationReardon, D. A., Vredenburgh, J. J., Desjardins, A., Peters, K. B., Gururangan, S., Sampson, J. H., Marcello, J. E., Herndon, J. E., McLendon, R. E., Janney, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0217-6 · Cited by 138
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 134
GILBERT, M. R., Wang, M., Aldape, K., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2006 · Cited by 134
Clinical trial end points for high-grade glioma: the evolving landscape
Reardon, D. A., Galanis, E., DeGroot, J. F., Cloughesy, T. F., Wefel, J. S., Lamborn, K. R., Lassman, A. B., Gilbert, M. R., Sampson, J. H., Wick, W., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq203 · Cited by 129
Self-citationSalvage therapy with single agent bevacizumab for recurrent glioblastoma
Chamberlain, M. C., & Johnston, S. K. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9957-6 · Cited by 124
PCV chemotherapy for recurrent glioblastoma multiforme
Kappelle, A. C., Postma, T. J., TAPHOORN, M. J. B., Groeneveld, G. J., van den Bent, M. J., van Groeningen, C. J., Zonnenberg, B. A., Sneeuw, K. C. A., & Heimans, J. J. (2001) · Neurology · doi:10.1212/wnl.56.1.118 · Cited by 118
Brandes, A. A., Basso, U., Reni, M., Vastola, F., Tosoni, A., Cavallo, G., Scopece, L., Ferreri, A. J. M., Panucci, M. G., Monfardini, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.019 · Cited by 117
Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme
Easaw, J. C., Mason, W. P., Perry, J., Laperrière, N., Eisenstat, D. D., Maestro, R. F. D., Bélanger, K., Fulton, D. S., & Macdonald, D. R. (2011) · Current Oncology · doi:10.3747/co.v18i3.755 · Cited by 111
Self-citationRechallenge with temozolomide in patients with recurrent gliomas
Wick, A., Pascher, C., Wick, W., Jauch, T., Weller, M., Bogdahn, U., & Hau, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5006-9 · Cited by 108
Self-citationA phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A., & Abrey, L. E. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.1.39 · Cited by 107
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M. O., & Nikkhah, G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-30 · Cited by 107
Kong, D., Lee, J.-I., Kim, J. H., Kim, S. T., Kim, W. S., Suh, Y., Dong, S. M., & Nam, D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop030 · Cited by 100
Brandes, A. A., Tosoni, A., Franceschi, E., Blatt, V., Santoro, A., Faedi, M., Amistà, P., Gardiman, M. P., Labianca, R., Bianchini, C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0926-8 · Cited by 99
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98
Beal, K. P., Abrey, L. E., & Gutin, P. H. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-2 · Cited by 94
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Verhoeff, J. J. C., Lavini, C., Linde, M. E. V., Stalpers, L. J. A., Majoie, C. B. L. M., Reijneveld, J. C., van Furth, W. R., & Richel, D. J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp591 · Cited by 94
Métellus, P., Coulibaly, B., Nanni, I., Fina, F., Eudes, N., Giorgi, R., Barrie, M., Chinot, O. L., Fuentes, S., Dufour, H., et al. (2009) · Cancer · doi:10.1002/cncr.24546 · Cited by 92
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Norden, A. D., Lesser, G. J., Drappatz, J., Ligon, K. L., Hammond, S. N., Lee, E. Q., Reardon, D., Fadul, C. E., Plotkin, S. R., Batchelor, T. T., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not040 · Cited by 92
Radiotherapeutic alternatives for previously irradiated recurrent gliomas
Combs, S. E., Debus, J., & Schulz–Ertner, D. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-167 · Cited by 92
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
Brandes, A. A., Ermani, M., Basso, U., Amistà, P., Berti, F., Scienza, R., Rotilio, A., Pinna, G. D., Gardiman, M. P., & Monfardini, S. (2001) · Annals of Oncology · doi:10.1023/a:1008336732273 · Cited by 91
PCV chemotherapy for recurrent glioblastoma
Schmidt, F., Fischer, J., Herrlinger, U., Dietz, K., DICHGANS, J., & Weller, M. (2006) · Neurology · doi:10.1212/01.wnl.0000197792.73656.c2 · Cited by 89
Self-citationReardon, D. A., Desjardins, A., Peters, K. B., Vredenburgh, J. J., Gururangan, S., Sampson, J. H., McLendon, R. E., Herndon, J. E., Sykes, A. D., Threatt, S., et al. (2011) · Cancer · doi:10.1002/cncr.26188 · Cited by 88
A novel tool to analyze MRI recurrence patterns in glioblastoma
Wick, W., Stupp, R., Beule, A.-C., Bromberg, J. E. C., Wick, A., Ernemann, U., Platten, M., Marosi, C., Mason, W. P., van den Bent, M. J., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-058 · Cited by 87
Self-citationPhase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Chua, S. L. L., Rosenthal, M. A., Wong, S., Ashley, D. M., Woods, A.-M., DOWLING, A. J., & Cher, L. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000188 · Cited by 85
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-1-39 · Cited by 85
Salvage temozolomide for prior temozolomide responders
Franceschi, E., Omuro, A. M. P., Lassman, A. B., Demopoulos, A. M., Nolan, C. P., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21564 · Cited by 83
Silvani, A., Eoli, M., Salmaggi, A., Lamperti, E., Maccagnano, E., Broggi, G., & Boiardi, A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000013479.64348.69 · Cited by 78
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
Reardon, D. A., Quinn, J. A., Rich, J. N., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Sathornsumetee, S., Badruddoja, M., McLendon, R. E., Provenzale, J., et al. (2005) · Cancer · doi:10.1002/cncr.21316 · Cited by 77
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
Addeo, R., Caraglia, M., Santi, M. S. D., Montella, L., Abbruzzese, A., Parlato, C., Vincenzi, B., Carraturo, M., Faiola, V., Genovese, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0329-z · Cited by 70
Kong, D., Lee, J.-I., Kim, W. K., Son, M. J., Lim, D. H., Kim, S. H., Park, K., Kim, J. W., Eoh, W., & Nam, D. (2006) · Oncology Reports · doi:10.3892/or.16.5.1117 · Cited by 70
Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Casorelli, I., Russo, M. T., & Bignami, M. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008784220276 · Cited by 67
Wen, P. Y., Prados, M. D., Schiff, D., Reardon, D. A., Cloughesy, T. F., Mikkelsen, T., Batchelor, T. T., Drappatz, J., Chamberlain, M. C., & de Groot, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2006 · Cited by 67
Self-citationScoccianti, S., Detti, B., Sardaro, A., Iannalfi, A., Meattini, I., Leonulli, B. G., Borghesi, S., Martinelli, F., Bordi, L., Ammannati, F., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283005075 · Cited by 66
Glioblastoma: Patterns of Recurrence and Efficacy of Salvage Treatments
Oh, J., Sahgal, A., Sanghera, P., Tsao, M. N., Davey, P., Lam, K., Symons, S. P., Aviv, R. I., & Perry, J. (2011) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100012166 · Cited by 63
Self-citationFrancesconi, A. B., Dupre, S., Matos, M., Martin, D., Hughes, B. G. M., Wyld, D., & Lickliter, J. D. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.12.009 · Cited by 62
Nagane, M., Kobayashi, K., Ohnishi, A., Shimizu, S., & Shiokawa, Y. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym132 · Cited by 62
Balmaceda, C. M., Peereboom, D. M., Pannullo, S. C., Cheung, Y. K., Fisher, P. G., Alavi, J. Β., Sisti, M. B., Chen, J., & Fine, R. L. (2008) · Cancer · doi:10.1002/cncr.23167 · Cited by 61
Fabrini, M. G., Silvano, G., Lolli, I. R., Perrone, F., Marsella, A., Scotti, V., & Cionini, L. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9739-6 · Cited by 61
Brandes, A. A., Ermani, M., Basso, U., Paris, M. K., Lumachi, F., Berti, F., Amistà, P., Gardiman, M. P., Iuzzolino, P., Turazzi, S., et al. (2002) · Oncology · doi:10.1159/000065718 · Cited by 59
Extended-schedule dose-dense temozolomide in refractory gliomas
GENOM Cooperative Group, Berrocal, A., Segura, P. P., Gil, M., Balañá, C., López, J. G., Yayá, R., Rodríguez, J., Reynés, G., Gallego, O. S., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9980-7 · Cited by 56
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
Stockhammer, F., Misch, M., Koch, A., Czabanka, M., Plotkin, M., Blechschmidt, C., Tuettenberg, J., & Vajkoczy, P. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0192-y · Cited by 56
Sadones, J., Michotte, A., Veld, P. I. '., Chaskis, C., Sciot, R., Menten, J. J., Joosens, E. J., Strauven, T., D'Hondt, L. A., Sartenaer, D., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.002 · Cited by 54
Chang, S. M., Prados, M. D., Yung, W. K. A., Fine, H. A., Junck, L., Greenberg, H. S., Robins, H. I., Mehta, M. P., Fink, K., Jaeckle, K. A., et al. (2004) · Cancer · doi:10.1002/cncr.20157 · Cited by 52
Groves, M. D., Puduvalli, V. K., GILBERT, M. R., Levin, V. A., Conrad, C. A., Liu, V., Hunter, K., Meyers, C., Hess, K. R., & Yung, W. K. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605189 · Cited by 50
ACNU-based chemotherapy for recurrent glioma in the temozolomide era
Hertler, C., Roth, P., Wick, W., Steinbach, J. P., Linnebank, M., Weller, M., & Eisele, G. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9728-9 · Cited by 46
Self-citationTreatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Boiardi, A., Silvani, A., Eoli, M., Lamperti, E., Salmaggi, A., Gaviani, P., Fiumani, A., Botturi, A., Falcone, C., Solari, A., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9540-6 · Cited by 45
Walbert, T., Gilbert, M. R., Groves, M. D., Puduvalli, V. K., Yung, W. K. A., Conrad, C. A., Bobustuc, G. C., Colman, H., Hsu, S. H., Bekele, B. N., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0313-7 · Cited by 32
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl, K., & Weller, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.670219 · Cited by 31
Self-citationMonitoring Radiographic Brain Tumor Progression
Mehta, A. I., Kanaly, C. W., Friedman, A. H., et al. (2011) · Toxins · doi:10.3390/toxins3030191 · Cited by 31
Should Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?
Weller, M., Wick, W., Hegi, M. E., Stupp, R., & Tabatabai, G. (2010) · Future Oncology · doi:10.2217/fon.10.113 · Cited by 27
Self-citationNeuroradiological Response Criteria for High-grade Gliomas
Lutz, K., Radbruch, A., Wiestler, B., Bäumer, P., Wick, W., & Bendszus, M. (2011) · Clinical Neuroradiology · doi:10.1007/s00062-011-0080-7 · Cited by 25
Self-citation2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies
Ahluwalia, M. S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.227 · Cited by 23
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan, D. T. M., Poon, W. S., Chan, Y. L., & Ng, H. (2005) · PubMed · Cited by 17
Evolution of care for patients with relapsed glioblastoma
Balañá, C., Villà, S., & Teixidor, P. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.152 · Cited by 6
Cited by
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationCurrent state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Glioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 518
Self-citation
Metadata
- Authors
- Weller, M., Cloughesy, T., Perry, J. R., & Wick, W.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-07
- Volume
- 15
- Issue
- 1
- Pages
- 4-27
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2121396361
- Cited by
- 771
- References
- 107
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.